BioMerieux : AG 2026 - 2025 Parent company financial statements

About this update from Biomerieux Sa

Parent company financial statements Parent company financial statements of bioMérieux SA for the fiscal years ended December 31, 2024 and 2025 Balance sheet Assets In millions of euros Gross 12/31/2025 Depreciation, amortization and impairment Net 12/31/2024 Net Intangible assets Development expenses 14.2 -14.2 - - Concessions, patents, licenses, trademarks, processes, information technology solutions, rights, and similar assets 278.2 -131.2 147.0 32.4 Goodwill 131.9 - 131.9 131.9 Other intangible assets 5.4 -4.7 0.7 1.1 Intangible assets under construction, advances and deposits 2.1 - 2.1 2.6 Property, plant and equipment Land 23.5 -1.6 21.9 20.6 Buildings 365.4 -231.4 134.0 137.7 Technical installations, industrial equipment and tools 403.8 -272.0 131.8 134.1 Other property, plant and equipment 70.8 -58.0 12.8 14.5 Property, plant and equipment under construction, advances, and deposits. 125.1 - 125.1 66.6 Non-current financial assets (a) Equity investments 1,354.5 -163.1 1,191.4 1,042.0 Receivables from equity investments 5.2 - 5.2 5.1 Other financial assets 188.3 -78.7 109.6 123.8 Other non-current financial assets 0.6 - 0.6 0.6 Total non-current assets (I) 2,969.1 -954.8 2,014.2 1,712.9 Inventories and work-in-progress Raw materials and other supplies 45.3 -2.8 42.4 45.7 Work-in-progress 30.2 -0.8 29.4 32.5 Finished products 41.6 -1.4 40.2 38.4 Goods held for sale 136.8 -5.6 131.2 117.6 Advances and deposits on orders 14.8 - 14.8 8.9 Receivables (b) Trade receivables 574.1 -13.8 560.3 514.9 Other receivables 91.1 - 91.1 75.5 Prepaid expenses 21.7 - 21.7 16.4 Investment securities Treasury shares 35.5 - 35.5 39.1 Other securities 178.1 - 178.1 133.8 Forward financial instruments and tokens held 1.3 - 1.3 3.0 Cash and cash pooling 409.2 -1.6 407.6 702.5 Total current assets (II) 1,579.6 -26.1 1,553.5 1,728.3 Loan issue costs (III) 0.2 - 0.2 0.3 Translation and valuation differences - Assets (IV) 2.1 - 2.1 9.1 TOTAL ASSETS (I + II + III + IV) 4,551.0 -980.9 3,570.1 3,450.6 (a) Of which due in less than one year 0.2 - 0.2 0.2 (b) Of which due in less than one year 619.0 -13.8 605.2 537.1 Shareholders' equity and liabilities In millions of euros 12/31/2025 12/31/2024 Share capital 12.0 12.0 Share, merger and acquisition premiums 74.4 74.4 Reserves Legal reserve 1.2 1.2 Reserves required by the articles of association 905.0 895.0 Regulatory reserves 1.0 1.0 Retained earnings 635.9 300.1 Net income for the year (profit or loss) 320.5 451.9 Capital expenditure subsidies 0.2 0.1 Statutory provisions 84.1 84.1 Total equity (I) 2,034.3 1,819.9 Provisions for risks 2.9 12.6 Provisions for charges 73.8 68.5 Total provisions (II) 76.6 81.1 Other bond issues 201.6 201.6 Borrowings and debts from credit institutions 0.1 0.1 Miscellaneous borrowings and financial debt 630.2 726.3 Forward financial instruments 1.5 0.5 Trade payables 327.4 334.7 Tax and social-security debts 247.6 237.6 Debts on fixed assets and related accounts 31.1 27.2 Other payables 14.0 16.3 Deferred income 4.5 4.6 Total debts (a) (III) 1,458.0 1,549.1 Translation and valuation differences - Liabilities (IV) 1.2 0.5 TOTAL LIABILITIES (I + II + III + IV) 3,570.1 3,450.6 (a) Of which due in less than one year 1,158.6 1,263.1 Profit & loss statement In millions of euros 2025 2024 Operating income Sales of goods 723.7 672.8 Production sold 970.5 967.9 Net amount of sales 1,694.2 1,640.7 Stored production -2.3 -1.5 Capitalized production 10.1 9.4 Subsidies 1.1 2.1 Reversals of amortization, impairment and provisions 45.2 28.9 Proceeds from disposals of property, plant and equipment and intangible assets 2.0 - Other income 0.9 0.1 Total operating income (I) 1,751.2 1,679.6 Operating expenses Purchases of goods -525.6 -488.0 Change in inventories 13.9 -20.3 Purchases of raw materials and other supplies -130.5 -130.4 Change in raw material inventories -3.0 -5.6 Other purchases and external expenses (a) -491.4 -469.5 Taxes, duties and similar taxes -20.3 -18.9 Wages and salaries -327.1 -311.1 Social security contributions -134.3 -128.9 Amortization and impairment expenses: On fixed assets: amortization expenses -64.0 -60.7 On fixed assets: impairment expenses -0.9 -0.0 On current assets: impairment expenses -12.3 -12.9 Provisions -4.6 -28.2 Carrying amounts of sold intangible assets and property, plant and equipment -12.0 - Other expenses -30.1 -18.8 Total operating expenses (II) -1,742.1 -1,693.4 1. OPERATING INCOME (I - II) 9.1 -13.8 (a) including property leasing agreement expenses -4.1 -4.5 In millions of euros Financial income From participating interests (b) From other securities and receivables from non-current assets (b) Other interest and similar income (b) Reversal of impairment and provisions Foreign exchange gains Income from sales of non-current financial assets Net proceeds from the sale of investment securities and cash instruments. Total financial income (III) Financial expenses Amortization and impairment expenses and provisions Interest and similar expenses (c) Foreign exchange losses Book value of sold non-current financial assets Net expenses from the sale of investment securities and cash instruments. Total financial expenses (IV) FINANCIAL INCOME (III - IV) NET INCOME BEFORE NON-RECURRING ITEMS AND TAX (I - II + III - IV) Non-recurring income (V) Non-recurring expenses (VI) NON-RECURRING INCOME (V - VI) Income taxes (VII) Total income (I + III + V) Total expenses (II + IV + VI + VII) PROFIT OR LOSS 2025 2024 349.9 480.3 14.7 21.7 8.5 6.1 7.8 17.0 115.9 100.4 0.0 - 3.6 4.7 500.4 630.3 -61.9 -42.2 -26.4 -32.2 -111.9 -103.1 - - -0.7 -0.7 -200.9 -178.2 299.6 452.0 308.7 438.3 14.0 31.9 -14.0 -35.0 -0.0 -3.1 11.9 16.7 2,265.6 2,341.8 -1,945.1 -1,889.9 320.5 451.9 14.7 -22.2 21.7 -27.4 including income from related parties including interests in related parties Notes to the Financial Statements bioMérieux is a French joint stock company (société anonyme) with a Board of Directors, governed by the French Commercial Code (Code de commerce) and all other applicable laws and regulations, registered with the Lyon Trade and Companies Register under number 673 620 399. The Company has been established in France since its incorporation. CONTENTS The Company's headquarters are located in Marcy l'Étoile (69280), France. NOTE 1 General accounting principles 328 NOTE 2 Information about the entity that prepares the consolidated financial statements 330 NOTE 3 Significant events of the fiscal year 330 NOTE 4 Non-current assets 331 NOTE 5 Inventories 341 NOTE 6 Trade and other receivables from current assets 341 NOTE 7 Due dates of receivables 342 NOTE 8 Cash and cash equivalents and investment securities 342 NOTE 9 Translation differences 343 NOTE 10 Equity and free shares grant plans 343 NOTE 11 Provisions for financial risks and losses 345 NOTE 12 Net debt 346 NOTE 13 Trade and other operating payables 348 NOTE 14 Debt schedule 349 NOTE 15 Accrued expenses and income 349 NOTE 16 Sales 349 NOTE 17 Research & Development expenses 350 NOTE 18 Personnel costs 350 NOTE 19 Net financial income 351 NOTE 20 Non-recurring income 352 NOTE 21 Corporate income tax 352 NOTE 22 Hedging instruments 353 NOTE 23 Off-balance sheet commitments 354 NOTE 24 Related parties 355 NOTE 25 Statutory Auditors' fees 356 ‌NOTE 1 General accounting principles The accounts have been prepared in accordance with Regulations 2014-03 of the French accounting standards authority (Autorité des normes comptables - ANC) updated to Regulation 2022-06 on the Modernization of Financial Statements (French general accounting plans - PCG). At December 31, 2025, the Company applied the new ANC Regulation 2022-06 on the general accounting plan for the first year. In particular, this regulation removes the "expense transfer" accounts and introduces a new, more restrictive definition of non-recurring income. Non-recurring income now includes: income and expenses directly related to a major and extraordinary event; accounting entries of a purely tax nature, as defined and provided for in the regulations of the French accounting standards authority (Autorité des normes comptables - ANC). This applies to the creation or reversal of regulated provisions, including accelerated depreciation recognized for tax purposes and defined in Article 214-8; changes in accounting policy that the entity is required to recognize in profit or loss, rather than equity, as a result of the application of tax rules; corrections of errors, except when correcting an entry that has been directly recorded to equity. This change in accounting regulations has no impact on the balance sheet at the beginning of the fiscal year. It impacts the presentation of the 2025 profit & loss statement as follows: Reclassifications of non-recurring income Capital gains and losses on Discontinuation In millions of euros Impact on 2025 Free share grant the disposal of fixed assets Other reclassifications of expense transfers Total operating income 6.2 -1.7 12.0 0.0 -4.2 Total operating expenses -9.6 -1.7 -12.0 -0.1 4.2 1. Operating income -3.5 -3.4 0.0 -0.1 - 2. Net financial income 0.0 - 0.0 - - 3. Net income before non-recurring -3.5 -3.4 0.0 -0.1 - items and tax Non-recurring income -32.9 -20.9 -12.0 -0.0 - Non-recurring expenses 36.4 24.3 12.0 0.1 - 4. Non-recurring income 3.5 3.4 -0.0 0.1 - PROFIT OR LOSS - - - - - Non-recurring expenses related to the free share grant reclassified as operating income are broken down into "wages," "social security contributions" and "other operating expenses." The new provisions of the Regulation apply since 2025, with no impact on the 2024 financial statements other than the reclassifications necessary for the new presentation of the balance sheet and profit & loss statement. In 2024, the balance sheet and profit & loss statement were presented as follows: BALANCE SHEET - ASSETS In millions of euros Net 12/31/2024 NON - CURRENT ASSETS Intangible assets 167.9 Property, plant and equipment 373.5 Investments and related receivables 1,047.1 Other non-current financial assets 124.4 Total 1,712.9 CURRENT ASSETS Inventories and work-in-progress 234.3 Trade receivables 514.9 Other operating receivables 51.3 Non-operating receivables 49.5 Cash and cash pooling 878.3 Total 1,728.3 Deferred charges spread over several years 0.3 Translation differences - losses 9.1 TOTAL ASSETS 3,450.6 BALANCE SHEET - LIABILITIES In millions of euros 12/31/2024 SHAREHOLDERS' EQUITY Share capital 12.0 Additional paid-in capital 74.4 Reserves 1,197.3 Statutory provisions and grants 84.3 Net income for the year 451.9 Total 1,819.9 Provisions 81.1 LIABILITIES Borrowings and financial debt 928.6 Trade payables 334.7 Other operating payables 258.6 Non-operating payables 27.2 Total 1,549.1 Translation differences - gains 0.5 TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES 3,450.6 PROFIT & LOSS STATEMENT In millions of euros 2024 Sales of goods and finished products 1,277.4 Other income 363.3 Sales 1,640.7 Production included in inventories (work-in-progress and finished products) -18.4 Capitalized production 9.4 Total production 1,631.7 Purchases -638.5 Change in raw material and instrument inventories -9.1 External expenses -449.5 Added value 534.6 Taxes other than income tax -16.8 Payroll and benefits -440.0 Gross operating income (EBITDA) 77.8 Depreciation, amortization and provisions -77.7 Other operating income (expense) -13.9 Operating income -13.8 Financial income and expenses -0.8 Net investment income 452.8 Net income before non-recurring items and tax 438.3 Non-recurring income -3.1 Income tax 16.7 ‌NET INCOME 451.9 NOTE 2 Information about the entity that prepares the consolidated financial statements The Company prepares consolidated financial statements which include the annual financial statements of its subsidiaries based on the full consolidation method whenever bioMérieux SA has effective control over those subsidiaries, or based on the equity method when the Company exercises significant leverage over the entities concerned. The Company has been included in the scope of consolidation on a fully consolidated basis by Compagnie Mérieux Alliance. Information about the entity that prepares the consolidated financial statements Entity preparing the consolidated financial statements of the largest group of entities of which the entity is a subsidiary ‌Entity preparing the consolidated financial statements of the smallest group of entities included in the above group of entities of which the entity is a subsidiary Compagnie Mérieux Alliance 17, rue Bourgelat, 69002 - Lyon SIREN 504,340,407 Institut Mérieux 17, rue Bourgelat, 69002 - Lyon SIREN 348,579,509 NOTE 3 Significant events of the fiscal year Financial investments In 2025, bioMérieux SA subscribed to several equity investments and capital increases in its portfolio for a total amount of €194.4 million, including the acquisition of the entire share capital of SpinChip Diagnostics for NOK 1.3 billion (€112.3 million) and the capital increase of some of its subsidiaries for €77.9 million. These events are detailed in Note 4.4. Employee share ownership plan In 2025, eligible Group employees participated in a private placement within an employee share ownership plan called "MyShare." Employees benefited from a share subscription price of €91.84 discounted by 20% compared with the reference price (€114.8) and a matching employer contribution of 100% of the subscription amount up to a maximum of €450 per employee. Group employees subscribed to 177,262 shares (of which 113,556 shares by French employees). The Company issued 203,210 shares to employees (of which 129,492 shares for French employees) taking into account the discount and the matching employer contribution. The cost of the plan for French employees, as recorded in operating income, is €4.8 million. The cost of the plan for employees of other Group companies has been fully passed on to the subsidiaries and has no impact on operating income. The difference between the reference share price (€114.8) and the cost price (€100.27) of the 203,210 shares granted to the Group's employees represents a gain €3 million in financial income. Significant subsequent events ‌There have been no significant events since the balance sheet date. NOTE 4 Non-current assets General framework Gross value In millions of euros Gross amount at the beginning of the fiscal year Increases Decreases Gross amount at year-end Intangible assets 346.9 131.7 -46.8 431.9 Property, plant and equipment 904.4 123.6 -39.3 988.7 Non-current financial assets 1,354.6 198.0 -4.1 1,548.5 TOTAL 2,605.9 453.3 -90.1 2,969.1 Amortization In millions of euros Duration of use Amortization method Accumulated amortization at the beginning of the year Increases: Allocations for the fiscal year Decreases Accumulated amortization at year-end Intangible assets 1 to 20 years straight-line 167.4 17.0 -34.4 150.0 Property, plant and equipment 3 to 40 years straight-line 528.8 47.0 -15.2 560.7 Non-current financial assets N/A N/A - - - - TOTAL 696.3 64.0 -49.6 710.7 Impairment In millions of euros Impairment losses at the beginning of the fiscal year Increases: allocation for the fiscal year Decreases: reversals for the fiscal year Impairment at year-end Intangible assets 11.5 - -11.5 0.0 Property, plant and equipment 2.1 0.9 -0.7 2.4 Non-current financial assets 183.1 59.8 -1.2 241.8 TOTAL 196.8 60.7 -13.3 244.1 Intangible assets Accounting principles Pursuant to ANC Regulation 2015-06, technical merger losses were allocated in January 2016 to specific intangible asset accounts relating to acquired goodwill, such as commercial goodwill, technology and customer relations. Historical goodwill and assets originating from the allocation of technical merger losses are not stand-alone items able to generate cash flow on their own. They are intrinsically attached to production plants, to the R&D supporting the acquired product line, to technology and to the sales forces that help move products through all the Group's distribution channels. Acquired goodwill is therefore grouped together with the other assets of the technological range to which they are linked in order to constitute a homogeneous and stand-alone range. In practice, tests are performed to group together assets that serve the same client typology (industrial microbiology laboratories) or health issue (pathology/detection of pathogens: microbiology, molecular biology or immunoassays). An impairment test is carried out systematically based on asset groups close to the groups identified at Group level (CGU) when analysis shows them to be fungible (monitoring and pooled management of acquired goodwill by technological product line and customer type). At each fiscal year-end, the net value of the asset groups thus identified is compared with the current value of assets as determined from the discounted net cash flows generated by these assets (including acquired goodwill). An impairment is recorded if a loss of value is observed. Lastly, no borrowing costs are included in the acquisition cost of intangible assets. Change Gross value Gross value In millions of euros Gross amount at the beginning of the fiscal year Increases Decreases Gross amount at year-end Development expenses 14.2 - - 14.2 Concessions, patents, licenses, trademarks, processes, information technology solutions, rights, and similar assets 182.8 129.9 -34.4 278.2 Goodwill 142.0 - -10.0 131.9 Other intangible assets 5.4 - - 5.4 Intangible assets under construction, advances and deposits 2.6 1.9 -2.3 2.1 TOTAL INTANGIBLE ASSETS 346.9 131.7 -46.8 431.9 The increases for the period are broken down as follows: In millions of euros items Acquisitions Creations Concessions, patents, licenses, trademarks, processes, information technology solutions, rights, and similar assets 2.1 127.8 - Intangible assets under construction, advances and deposits - 1.2 0.7 TOTAL INTANGIBLE ASSETS 2.1 129.0 0.7 Increases for the year Transfers between Breakdown of increases Additions In 2025, bioMérieux SA acquired the intellectual property rights to the technologies of SpinChip Diagnostic ASA for €105.3 million and Day Zero Diagnostics for €18.1 million. SpinChip Diagnostics ASA technology consists of the development of a high-performance point-of-care immunoassay system, specifically designed for the detection of myocardial infarction. Day Zero Diagnostics has developed innovative technologies that integrate sample preparation directly from whole blood, sequencing, and advanced identification and antibiotic susceptibility testing (ID/AST). The decreases for the period are broken down as follows: In millions of euros items Disposals Discontinuation Concessions, patents, licenses, trademarks, processes, information technology solutions, rights, and similar assets - -0.3 -34.1 Goodwill - - -10.0 Intangible assets under construction, advances and deposits -2.3 - - TOTAL INTANGIBLE ASSETS -2.3 -0.3 -44.1 Decreases for the fiscal year Transfers between Breakdown of decreases Disposals The decommissioning of patents and IT solutions concerns obsolete or terminated licenses, software, and IT projects. The discontinuation of the NUCLISENS® range commercialization resulted in the write-off of goodwill for a gross amount of €10 million, fully depreciated Amortization Amortization In millions of euros Duration of use Amortization method Accumulated amortization at the beginning of the year Increases: allocations Decreases Total accumulated amortization at year-end Development expenses 2 to 5 years Straight-line 14.2 - - 14.2 Concessions, patents, licenses, trademarks, processes, information technology solutions, rights, and similar assets 1 to 20 years Straight-line 148.9 16.6 -34.4 131.1 Other intangible assets 1 to 15 years Straight-line 4.3 0.3 - 4.7 TOTAL INTANGIBLE ASSETS 167.4 17.0 -34.4 150.0 Amortization expenses for the period are broken down as follows: Breakdown of allocations Allocations for the fiscal year On items amortized on a straight-line On items amortized Non-recurring using another allocations In millions of euros basis method Concessions, patents, licenses, trademarks, processes, 16.6 - - information technology solutions, rights, and similar assets Other intangible assets 0.3 - - TOTAL INTANGIBLE ASSETS 17.0 - - Amortization reversals are explained as follows: Breakdown of decreases Decreases for the fiscal year In millions of euros Items sold Discontinued items Concessions, patents, licenses, trademarks, processes, -0.3 -34.1 information technology solutions, rights, and similar assets TOTAL INTANGIBLE ASSETS -0.3 -34.1 Impairment losses Impairment In millions of euros Impairment at the beginning of the year Increases: allocation Decreases: reversals Impairment at year-end Concessions, patents, licenses, trademarks, processes, information technology solutions, rights, and similar assets 1.5 - -1.5 0.0 Goodwill 10.0 - -10.0 - TOTAL INTANGIBLE ASSETS 11.5 - -11.5 0.0 Technical losses Technical merger losses are allocated as follows: In millions of euros Gross value Amortization Net value AES CHEMUNEX Goodwill 111.0 - 111.0 Technology 6.4 4.7 1.6 Customer relationships 5.4 4.7 0.7 Total AES Chemunex 122.8 9.4 113.4 ARGENE Goodwill 19.4 - 19.4 Technology 11.5 11.1 0.4 Total Argene 30.9 11.1 19.8 CEERAM Technology 2.4 2.4 - Total Ceeram 2.4 2.4 - TOTAL 156.1 23.0 133.2 Goodwill impairment tests were performed on AES Chemunex and Argene No indication of loss of value has been identified. Property, plant and equipment Accounting principles Property, plant and equipment are shown on the balance sheet at purchase or production cost. In accordance with the asset recognition rules in effect since January 1, 2005, components whose cost is significant in relation to the total cost of the main asset are recognized and depreciated separately if their useful life is not the same as that of the main asset. The only property, plant and equipment to which this method applies are buildings. Impairment tests are carried out for property, plant and equipment whenever events or market developments indicate that an asset may have declined in value. If the net book value exceeds the recoverable amount, an impairment loss is recognized to reduce the assets to their realizable value. Most capitalized instruments are installed at customers' sites. Lastly, no borrowing costs are included in the acquisition cost of property, plant and equipment. Change Gross value Gross value In millions of euros Gross amount at the beginning of the fiscal year Increases Decreases Gross amount at year-end Land 22.1 1.4 - 23.5 Buildings 356.9 11.6 -3.2 365.4 Technical installations, industrial equipment and tools 387.7 27.0 -10.9 403.8 Other property, plant and equipment 71.1 2.8 -3.1 70.8 Property, plant and equipment under construction, advances, and deposits. 66.6 80.7 -22.2 125.1 TOTAL PROPERTY, PLANT AND EQUIPMENT 904.4 123.6 -39.3 988.7 The increases for the period are broken down as follows: Breakdown of increases Increases for the year Transfers between Additions In millions of euros items Acquisitions Creations Land 0.2 1.3 - Buildings 7.8 3.8 - Technical installations, industrial equipment and tools 13.6 4.2 9.2 Other property, plant and equipment 0.9 1.9 - Property, plant and equipment under construction, advances, and deposits. - 80.5 0.2 TOTAL PROPERTY, PLANT AND EQUIPMENT 22.5 91.7 9.4 Increases during the period mainly include investments made in the production of BioFire and SpotFire reagents at the La Balme site for €32.6 million, the construction of a new building in Marcy The decreases for the period are broken down as follows: dedicated to molecular biology for €11.8 million, and the construction of a research and development building in Grenoble for €9.3 million. Breakdown of decreases In millions of euros items Disposals Discontinuation Buildings - - -3.2 Technical installations, industrial equipment and tools - -3.8 -7.1 Other property, plant and equipment - -0.2 -2.9 Property, plant and equipment under construction, advances, and deposits. -22.2 - - TOTAL PROPERTY, PLANT AND EQUIPMENT -22.2 -4.0 -13.1 Decreases for the fiscal year Transfers between Disposals In 2025, an amount of €22.2 million in property, plant and equipment under construction at the beginning of the fiscal year was brought into service, consisting mainly of production lines and industrial equipment. Amortization Amortization In millions of euros Duration of use Amortization method Accumulated amortization at the beginning of the year Increases: allocations Decrea- ses Accumulated amortization at the balance sheet date Land N/A N/A 1.5 0.1 - 1.6 Buildings 10 to 40 years Straight-line 218.6 15.6 -3.2 231.0 Technical installations, industrial equipment and tools 3 to 10 years Straight-line 252.2 27.0 -9.2 270.1 Other property, plant and equipment 3 to 10 years Straight-line 56.5 4.3 -2.9 58.0 Property, plant and equipment under construction, advances, and deposits. N/A N/A - - - - TOTAL PROPERTY, PLANT AND EQUIPMENT 528.8 47.0 -15.2 560.7 Amortization expenses for the period are broken down as follows: Breakdown of allocations Allocations for the fiscal year In millions of euros On items amortized on a straight-line basis On items amortized Non-recurring using another method allocations Land 0.1 - - Buildings 15.6 - - Technical installations, industrial equipment and tools 27.0 - - Other property, plant and equipment 4.3 - - TOTAL PROPERTY, PLANT AND EQUIPMENT 47.0 - - Amortization reversals are explained as follows: Breakdown of decreases Decreases for the fiscal year Items sold Items taken out In millions of euros of service Buildings - -3.2 Technical installations, industrial equipment and tools -2.0 -7.1 Other property, plant and equipment - -2.9 TOTAL PROPERTY, PLANT AND EQUIPMENT -2.0 -13.1 Impairment losses Impairment In millions of euros Impairment at the beginning of the year Increases: allocation Decreases: reversals Impairment at year-end Buildings 0.7 - -0.3 0.4 Technical installations, industrial equipment and tools 1.4 0.9 -0.4 2.0 TOTAL PROPERTY, PLANT AND EQUIPMENT 2.1 0.9 -0.7 2.4 Non-current financial assets Accounting principles Non-current financial assets are recognized at their purchase price. An impairment loss is recognized on equity investments whenever their value in use falls below their acquisition cost. Value in use is initially estimated at the net book value of the subsidiary's assets at the closing date. This may be adjusted to reflect the value of any unrecognized identifiable assets (particularly real estate or technologies). Depending on the economic and financial condition of the subsidiary, value in use may also be estimated taking account of sales, borrowings and any associated technological assets and real estate. Given the specific nature of certain investments, in some cases value in use may be measured by estimating the enterprise value based on discounted future cash flows or on observable market financial inputs. Non-controlling interests held in unlisted companies are measured based on various criteria including the economic outlook, the net equity of the investment or the valuation used based on recent investments in these shares. Other investments are subjected to impairment whenever their market value falls below cost. The market value of listed securities corresponds to the average trading price during the last month of the fiscal year. Other non-current financial assets include treasury shares purchased under a liquidity agreement with an investment firm for the specific purpose of maintaining an orderly market in the Company's shares. Treasury stock is measured at its average trading price during the last month of the fiscal year. Change Gross value Gross value In millions of euros Gross amount at the beginning of the fiscal year Increases Decreases Gross amount at year-end Equity investments 1,161.8 192.6 - 1,354.5 Receivables from equity investments 6.2 2.9 -3.9 5.2 Other financial assets 186.0 2.4 -0.1 188.3 Other non-current financial assets 0.6 0.1 -0.1 0.6 TOTAL NON-CURRENT FINANCIAL ASSETS 1,354.6 198.0 -4.1 1,548.5 Acquisition of SpinChip Diagnostics ASA In 2025, bioMérieux SA acquired the entire Norwegian company SpinChip Diagnostics ASA for NOK 1.3 billion, or €112.3 million. During the previous year, bioMérieux SA acquired a stake in this company for NOK 115 million (€9.9 million), and subscribed to a capital increase of NOK 12 million (€1 million). Financial support to subsidiaries and minority interests In 2025, bioMérieux SA subscribed to several capital increases of its subsidiaries, totaling €77.9 million, to support their commercial activities, acquisitions, and address cash difficulties stemming from currency devaluations: bioMérieux China for $44.7 million, i.e. €38.3 million; bioMérieux Egypt for €13 million; bioMérieux Argentina for €8 million; bioMérieux Colombia for $7 million, i.e. €6 million; bioMérieux Brazil for 36.9 million Brazilian reals, i.e. €5.9 million; bioMérieux Nigeria for an amount of €3.4 million, through the conversion of debts into capital; bioMérieux Chile for €2.5 million; bioMérieux Regional Headquarters in Saudi Arabia, for an amount of SAR 3 million (€0.7 million). Additionally, bioMérieux SA also participated in the capital increase of Aurobac Therapeutics SAS for an amount of €2.5 million. Transactions relating to fixed assets bioMérieux SA acquired a €1.3 million stake in Plair, thereby strengthening its commitment to real-time microbial detection and air sampling solutions for the pharmaceutical industry. Lastly, bioMérieux SA invested €0.4 million in Allergen Alert, a company working on the design of a system for non-professionals to quickly and reliably test for allergens in food. Impairment losses Impairment losses In millions of euros Impairment at the beginning of the year Increases: allocation Decreases: reversals Impairment at year-end Equity investments 119.9 43.3 -0.0 163.1 Receivables from equity investments 1.1 - -1.1 - Other financial assets 62.2 16.5 -0.1 78.7 TOTAL NON-CURRENT FINANCIAL ASSETS 183.1 59.8 -1.2 241.8 Allocations to impairment of equity investments amounted to €43.3 million over the fiscal year, and relate to impairment of the shares in the subsidiaries bioMérieux China for €33 million, bioMérieux Egypt for €7.6 million, and bioMérieux Nigeria for €2.6 million. Allocations to impairment of other fixed assets relate to impairment of the shares of Oxford Nanopore Technologies for €16.5 million (impairment losses calculated on the basis of the December 2025 stock exchange price compared to the acquisition price). List of subsidiaries and minority interests See table below. LIST OF SUBSIDIARIES AND MINORITY INTERESTS AT DECEMBER 31, 2025 Financial information Subsidiaries and minority interests Book value of securities held Net amount of loans and advances made by the Company (In millions of euros) Amount of commitments given by the Company (In millions of euros) Pre-tax sales for the last fiscal year (In millions of euros) Net profit or net loss of the last fiscal year (In millions of euros) Dividends received by Company during the fiscal year (In millions of euros) Notes (in millions of euros) Gross Net Shareholders' equity* Share of capital held (in %) INFORMATION CONCERNING SUBSIDIARIES (OVER 50% OWNED BY BIOMÉRIEUX SA) 1. Detailed information for each subsidiary (1) 1,211.4 1,062.0 125.1 93.0 342.8 AB bioMérieux 47.8 100.0% 74.2 4.3 0.0 0.0 0.0 0.0 0.0 01/01/2025- 12/31/2025 bioMérieux West Africa 890.5 100.0% 0.3 0.3 0.0 0.0 0.0 1.4 0.0 01/01/2025- 12/31/2025 bioMérieux Germany 29.1 100.0% 3.8 3.8 0.0 0.0 141.1 2.6 1.0 01/01/2025- 12/31/2025 bioMérieux Algeria 293.9 100.0% 0.6 0.6 0.0 0.0 0.6 0.4 0.0 01/01/2025- 12/31/2025 bioMérieux Saudi Arabia 4.1 100.0% 0.7 0.7 0.0 0.0 0.0 0.2 0.0 01/01/2025- 12/31/2025 bioMérieux Argentina 24,236.3 99.1% 16.3 16.3 0.0 0.3 27.9 5.3 0.0 01/01/2025- 12/31/2025 bioMérieux Austria 1.2 100.0% 0.1 0.1 0.0 0.0 30.5 1.0 1.6 01/01/2025- 12/31/2025 bioMérieux Australia 11.7 100.0% 23.8 23.8 0.0 0.7 36.1 0.8 0.5 01/01/2025- 12/31/2025 Financial information Subsidiaries and minority interests Book value of securities held Net amount of loans and advances made by the Company (In millions of euros) Amount of commitments given by the Company (In millions of euros) Pre-tax sales for the last fiscal year (In millions of euros) Net profit or net loss of the last fiscal year (In millions of euros) Dividends received by Company during the fiscal year (In millions of euros) Notes (in millions of euros) Gross Net Shareholders' equity* Share of capital held (in %) bioMérieux Brazil 147.0 100.0% 67.1 33.6 0.0 10.9 42.6 0.3 0.0 01/01/2025- 12/31/2025 bioMérieux Belgium 3.0 100.0% 0.3 0.3 0.0 0.0 36.5 1.5 3.9 01/01/2025- 12/31/2025 bioMérieux Canada 11.9 100.0% 20.5 20.5 0.0 0.0 64.4 1.6 0.9 01/01/2025- 12/31/2025 bioMérieux Chile 15,631.5 100.0% 5.6 5.6 0.0 0.0 33.7 1.1 0.0 01/01/2025- 12/31/2025 bioMérieux China 2,202.8 100.0% 228.6 195.6 0.0 0.6 27.7 0.7 0.0 01/01/2025- 12/31/2025 bioMérieux Colombia 108.7 100.0% 14.0 14.0 0.0 0.0 45.4 2.7 0.0 01/01/2025- 12/31/2025 bioMérieux Korea 27,994.8 100.0% 0.7 0.7 0.0 10.0 53.3 1.8 0.0 01/01/2025- 12/31/2025 bioMérieux Denmark 6.7 100.0% 0.5 0.5 0.0 0.0 9.6 0.3 0.5 01/01/2025- 12/31/2025 bioMérieux Spain 36.8 100.0% 0.6 0.6 0.0 0.0 130.0 4.6 6.0 01/01/2025- 12/31/2025 bioMérieux Egypt 303.5 100.0% 14.5 5.4 0.0 0.0 2.1 -7.0 0.0 01/01/2025- 12/31/2025 bioMérieux Greece 7.3 100.0% 4.1 4.1 0.0 3.0 22.6 0.0 0.0 01/01/2025- 12/31/2025 bioMérieux India 4,322.3 99.9% 18.1 18.1 0.0 21.3 107.6 4.1 0.0 01/01/2025- 12/31/2025 bioMérieux Inc. 2,250.0 100.0% 524.9 524.9 55.8 12.3 2,556.9 658.3 303.8 01/01/2025- 12/31/2025 bioMérieux Italy 54.6 100.0% 12.8 12.8 11.9 25.8 186.8 10.6 4.0 01/01/2025- 12/31/2025 bioMérieux Japan 2.6 100.0% 15.4 15.4 15.4 0.5 116.4 5.0 1.4 01/01/2025- 12/31/2025 bioMérieux Kenya 112.4 100.0% 0.3 0.3 0.0 0.0 0.0 0.0 0.0 01/01/2025- 12/31/2025 bioMérieux Mexico 414.5 100.0% 24.7 24.7 27.1 0.0 69.5 0.6 0.0 01/01/2025- 12/31/2025 bioMérieux Nigeria 1,343.1 100.0% 4.7 0.8 0.0 0.0 0.7 -0.1 0.0 01/01/2025- 12/31/2025 bioMérieux Norway 5.0 100.0% 0.3 0.3 0.3 0.0 7.1 0.2 0.3 01/01/2025- 12/31/2025 bioMérieux Philippines 72.9 100.0% 0.2 0.2 0.0 1.5 22.7 0.4 0.0 01/01/2025- 12/31/2025 bioMérieux Poland 47.6 100.0% 1.5 1.5 0.9 0.0 43.6 1.4 0.0 01/01/2025- 12/31/2025 bioMérieux Portugal 7.7 100.0% 2.0 2.0 0.0 0.5 24.4 1.3 1.0 01/01/2025- 12/31/2025 Financial information Subsidiaries and minority interests Book value of securities held Net amount of loans and advances made by the Company (In millions of euros) Amount of commitments given by the Company (In millions of euros) Pre-tax sales for the last fiscal year (In millions of euros) Net profit or net loss of the last fiscal year (In millions of euros) Dividends received by Company during the fiscal year (In millions of euros) Notes (in millions of euros) Gross Net Shareholders' equity* Share of capital held (in %) bioMérieux Russia 1,307.3 100.0% 1.3 1.3 0.0 0.0 17.8 2.1 0.0 01/01/2025- 12/31/2025 bioMérieux South Africa 184.9 100.0% 5.4 5.4 5.2 0.0 26.9 0.5 0.0 01/01/2025- 12/31/2025 bioMérieux Sweden 11.2 100.0% 0.2 0.2 1.8 2.8 30.8 0.5 0.5 01/01/2025- 12/31/2025 bioMérieux Switzerland 4.1 100.0% 0.6 0.6 0.0 0.0 50.2 1.9 2.2 01/01/2025- 12/31/2025 bioMérieux Suzhou Biotech Co. 388.7 100.0% 80.2 80.2 0.0 0.0 23.2 -0.6 0.0 01/01/2025- 12/31/2025 bioMérieux Thailand 117.9 100.0% 0.9 0.9 0.0 0.8 17.8 0.4 0.5 01/01/2025- 12/31/2025 bioMérieux Turkey 961.2 100.0% 17.0 17.0 0.0 0.0 38.9 5.4 0.6 01/01/2025- 12/31/2025 bioMérieux UK 15.6 100.0% 1.2 1.2 4.0 0.7 109.9 2.8 0.0 01/01/2025- 12/31/2025 bioMérieux Vietnam 12.5 100.0% 0.2 0.2 0.0 0.0 0.0 0.0 0.0 01/01/2025- 12/31/2025 BTF 60.4 100.0% 13.6 13.6 0.0 1.2 35.1 18.6 14.1 01/01/2025-12/31/2025 Lumed Inc. 11.1 100.0% 9.7 9.7 2.8 0.0 0.3 -1.5 0.0 01/01/2025-12/31/2025 2. Overall information for equity investments not included in (1) 126.8 124.3 78.9 2.4 7.1 349.9 1,338.2 1,186.4 204.0 95.4 A. TOTAL SUBSIDIARIES INFORMATION CONCERNING EQUITY INVESTMENTS (10% TO 50% OF CAPITAL HELD BY BIOMÉRIEUX SA) Aurobac Therapeutics SAS 13.1 12.5% 5.0 5.0 0.0 0.0 0.0 -4.7 0.0 01/01/2024- 12/31/2024 2. Overall information for equity investments not included in (1) 4.2 0.0 1.6 0.0 0.0 1. Detailed information for each subsidiary (1) 5.0 5.0 0.0 0.0 0.0 B. TOTAL MINORITY INTERESTS 9.2 5.0 1.6 0.0 0.0 C. TOTAL SUBSIDIARIES AND MINORITY INTERESTS (A + B) 1,347.4 1,191.4 205.7 95.4 349.9 * In transaction currencies. ‌NOTE 5 Inventories Accounting principles Inventories are measured at the lower of cost and net realizable value. Inventories of raw materials, consumables and goods for resale are measured at their purchase price plus related expenses using the FIFO method. Work-in-progress and finished products are measured at their actual production cost. Inventories are written down where necessary, taking into account selling prices, obsolescence, residual shelf life, product condition, sale prospects and, in the case of spare parts, changes in the corresponding instruments' installed base. Change Inventories and work-in-progress In millions of euros 12/31/2025 12/31/2024 Raw materials other supplies 45.3 48.2 Work-in-progress 30.2 33.9 Finished products 41.6 40.1 Goods held for sale 136.8 122.9 TOTAL 253.9 245.2 Impairment of inventories and work-in-progress In millions of euros 12/31/2025 12/31/2024 Method used to calculate impairment Raw materials other supplies -2.8 -2.5 Expiration, use, scrapping Work-in-progress -0.8 -1.4 Identified risks of non-use Finished products -1.4 -1.6 Sales prospects and scrapping Goods held for sale -5.6 -5.3 Sales prospects and scrapping TOTAL -10.6 -10.9 ‌The net value of inventories increased by €8.9 million compared with December 31, 2024, mainly due to an €11.7 million increase in inventories of BioFire reagents. NOTE 6 Trade and other receivables from current assets Accounting principles Receivables are recognized at face value. An impairment loss is recognized when there is a risk of non-recovery. Change Trade receivables In millions of euros 12/31/2025 12/31/2024 Gross trade receivables 574.1 537.1 Impairment losses -13.8 (a) -22.2 NET VALUE 560.3 514.9 (a) The decrease compared with 2024 is due to the absence of impairment of intra-group trade receivables at December 31, 2025, compared with €8.4 million at December 31, 2024. Other operating receivables In millions of euros 12/31/2025 12/31/2024 Advances and deposits 14.8 (a) 8.9 Prepaid expenses 21.7 (b) 16.4 Other receivables 91.1 (c) 75.5 TOTAL 127.5 100.8 Of which €10.4 million in advances paid, unused portion at December 31, 2025, which will be charged to future royalties over the next five years. Prepaid expenses primarily consist of external expenses. ‌Including VAT receivables of €23.3 million at December 31, 2025, (against €19.1 million at December 31, 2024). Other receivables also include research tax credit receivables. NOTE 7 Due dates of receivables Statement of receivable due dates In millions of euros Gross amounts Due within 1 year Due in more than 1 year Receivables from non-current assets 45.6 40.0 5.6 Receivables from current assets 680.0 625.6 54.3 (a) Prepaid expenses 21.7 20.2 1.5 TOTAL 747.3 685.8 61.4 ‌(a) Receivables from current assets due in more than one year mainly correspond to research tax credit receivables. NOTE 8 Cash and cash equivalents and investment securities Accounting principles Cash and cash equivalents include available cash and short-term investments. Changes in the cash pool are valued at the average monthly exchange rate. Cash pooling accounts are remeasured at the end of the month at the closing rate. This remeasurement is offset by an entry to financial income and expense reflecting currency hedges related to these positions. Change Cash and cash equivalents and investments In millions of euros 12/31/2025 12/31/2024 Cash investments 213.6 172.9 Lender cash pooling 224.0 529.8 Cash 183.0 172.9 Financial instruments 1.8 2.8 TOTAL CASH AND CASH EQUIVALENTS 622.4 878.3 Cash investments break down as follows: Investments In millions of euros 12/31/2025 12/31/2024 Investment Classification ISIN Code Treasury shares Equities FR0013280286 35.5 39.1 BNP PARIBAS ISR IC money market fund Euro money-market fund FR0007009808 36.0 - BNP PARIBAS SIGNATURE R money market fund Euro money-market fund FR0013245651 20.1 48.5 AMUNDI EURO LIQUIDITY money market fund Euro money-market fund FR0010251660 56.1 49.8 Time-deposit accounts Euro money-market fund N/A 65.8 35.4 TOTAL 213.6 172.9 Short-term investments include 331,541 shares purchased in connection with the establishment of a hedging program to cover the cost of the various free share grant plans and the employee share ownership programs. ‌Net debt is discussed in Note 12.1. NOTE 9 Translation differences Accounting principles In application of regulation ANC 2015-05, income and expenses in foreign currencies are recognized at their value in euros on the transaction date based on the average monthly exchange rate. Foreign exchange gains or losses on commercial transactions that result from differences in rates between the transaction date and the settlement date are recognized on the corresponding line in the profit & loss statement (sales and purchases). Receivables and payables in foreign currencies are converted based on their exchange rate on the closing date of the fiscal year. Differences resulting from this valuation were recognized under unrealized translation differences. Provisions are created for unrealized translation differences (losses) and are recognized in income (sales and purchases) whenever the receivable or payable is related to a business transaction. When, for business transactions with relatively close maturities, unrealized foreign exchange gains and losses may be considered as contributing to an overall currency position, the amount added to the provision for exchange rate risks is capped at the excess of losses over gains. This estimate of losses factors in, when applicable, the hedge rate on the derivatives covering such transactions. Foreign exchange gains and losses concerning financial flows are recognized in financial income and expenses. Translation differences concerning cash pooling are recognized in income, as are hedging instruments, symmetrically with the hedged item. Translation differences - losses In millions of euros 12/31/2025 12/31/2024 On borrowings and operating receivables 0.8 6.0 On borrowings and financial receivables 1.3 3.1 TOTAL 2.1 9.1 Translation differences - gains In millions of euros 12/31/2025 12/31/2024 On borrowings and operating receivables 1.2 0.5 ‌TOTAL 1.2 0.5 NOTE 10 Equity and free shares grant plans Accounting principles As of December 31, 2024, the Company applies ANC Regulation 2024-02 on the recognition of energy efficiency certificates. Energy savings certificates are now recognized in operating income at the disposal date, and those prior to 2024 have been reclassified as retained earnings for an amount of €1.5 million. Change in equity Change in shareholders' equity In millions of euros Amount at the beginning of the fiscal year Net income for the year Dividends paid Statutory provisions and grants Amount at the end of the fiscal year Share capital 12.0 12.0 Additional paid-in capital 74.4 74.4 Reserves & income 1,649.2 320.5 -106.1 1,863.6 Statutory provisions 84.1 84.1 Subsidies 0.1 0.0 0.2 TOTAL 1,819.9 320.5 -106.1 0.0 2,034.3 The Company's share capital amounted to €12,029,370 at December 31, 2025 and was divided into 118,361,220 shares with a total of 152,167,288 voting rights (of which 75,630,589 shares carry double voting rights). Following a decision taken by the Annual General Meeting of March 19, 2001, the Company's articles of association no longer refer to a par value for its shares. No rights or securities with a dilutive impact on capital were outstanding at December 31, 2025. The following table presents the Company's free share grant plans: At December 31, 2025, the Company held: 41,528 treasury shares under a liquidity agreement with an outside firm. In 2025, the Company purchased 1,101,650 and sold 1,097,784 treasury shares; 331,541 treasury shares were purchased as part of a hedging program for the various free share grant plans and employee share ownership plans. At December 31, 2025, these shares were not specifically allocated to one plan. In 2025, the Company purchased 375,000 shares and awarded 445,519. Date on which plans opened Total Number of shares 2022 2023 2024 2025 Initial number of options granted 272,218 287,538 406,257 369,255 1,335,268 Options canceled -29,909 -37,903 -61,366 -110,995 -240,173 (a) Number of shares remitted over the period -242,309 - - - -242,309 NUMBER OF SHARES TO BE REMITTED AT THE BALANCE SHEET DATE - 249,635 344,891 258,260 852,786 (a) Of which 77,719 shares canceled due to employee departures and 162,454 shares canceled due to assumptions that performance criteria would be met. Between 2022 and 2025, the Board of Directors granted free shares to certain employees and corporate officers. These plans specify that the free shares will have a vesting period of three years. Vesting conditions are related to continuous employment conditions and performance criteria subject to the achievement of objectives based on revenue and contributive operating income before non-recurring items, growth in these indicators, or the achievement of specific non-financial objectives. The performance shares are no longer subject to a lock-up period if the vesting period is at least two years. The lock-up period may be waived for shares granted to non-French tax residents provided that the shares concerned are subject to a three-year vesting period. In 2025, after taking into account all free shares that were re-invoiced, a net expense of €19.3 million was recognized in operating income, compared to a net expense of €11.7 million the previous year. At December 31, 2025, the company considered that the performance criteria would be met for 852,786 free shares. However, 162,454 free shares are considered canceled due to the risk of the performance criteria will not be met. With the 331,541 treasury shares held at December 31, 2025, the Company will have to purchase a maximum of 521,245 additional shares at a cost of €57 million, based on the share price at December 31, 2025, to cover existing plans. Change in regulated provisions and investment grants Regulated provisions and investment subsidies In millions of euros Amount at the beginning of the fiscal year Increases: allocations for the fiscal year Decreases: reversals for the fiscal year Amount at the end of the fiscal year Accelerated depreciation and amortization 78.1 13.6 -13.5 78.2 Provisions for price increases 6.0 0.4 -0.5 6.0 Capital expenditure subsidies 0.1 0.0 -0.0 0.2 ‌TOTAL 84.3 14.0 -14.0 84.3 NOTE 11 Provisions for financial risks and losses Change Provisions for financial contingencies and losses In millions of euros Amount at the beginning of the fiscal year Increases: allocations for the fiscal year Decreases: reversals for the fiscal year Used N/A Amount at the end of the fiscal year Provisions for risks 12.6 2.9 -12.4 -0.2 2.9 Guarantees given to customers 0.5 0.8 -0.5 - 0.8 Foreign exchange losses 9.1 2.1 -9.1 - 2.1 Financial risks 2.8 - -2.8 - - Other risks 0.2 - - -0.2 - Provisions for charges 68.5 33.5 -26.6 -1.6 73.8 Free share grant 40.1 29.6 -22.6 - 47.2 Long-service awards and end-of career benefits 23.3 - -2.1 - 21.2 Other expenses 5.1 3.8 -1.9 -1.6 5.4 TOTAL 81.1 36.3 -38.9 -1.9 76.6 Provisions for pensions and other post-employment benefits Post-employment benefit obligations and similar commitments are calculated using actuarial methods based on the following assumptions: Retirement benefits Long-service awards 12/31/2025 12/31/2024 12/31/2025 12/31/2024 Salary increase rate 3.00% 3.00% 3.00% 3.00% Discount rate 4.00% 3.30% 3.85% 3.10% Employee mobility rate (a) 0 to 7% 0 to 7% 0 to 7% 0 to 7% Average duration 12.7 13.2 8.7 8.9 (a) Depending on the age and status of the employee (managerial/non-managerial). The actuarial valuation of employee benefit obligations is as follows: Retirement benefits Long-service awards In millions of euros 12/31/2025 12/31/2024 12/31/2025 12/31/2024 Present value of obligation 40.2 41.0 16.1 16.2 Fair value of hedging assets 35.1 34.0 NET SITUATION 5.1 7.1 16.1 16.2 ‌The Company's obligations relating to retirement benefits are prefinanced by means of an insurance contract. The retirement benefits scheme represented a net debt of €5.1 million at December 31, 2025 vs. €7.1 million at December 31, 2024. NOTE 12 Net debt Statement of changes in net debt The statement of changes in net debt includes all changes in borrowings and financial debts, regardless of maturity, net of cash and short-term bank borrowings. It lists separately: cash flows from operating activities; cash flows from investment activities; cash flows relating to shareholders' equity. Cash flow from operating activities for the fiscal year corresponds to the aggregate of net income, depreciation and amortization, net additions to provisions (impairment and contingencies and losses), less capital gains or losses on disposals of fixed assets. Net debt corresponds to the Company's financial situation with regard to financing third parties outside of operating payables. This aggregate is determined by the sum of bond and banking debt (short-, medium- and long-term) and current accounts in credit, less cash, investment securities and current accounts in debit. Table of changes in net debt In millions of euros 12/31/2025 12/31/2024 Net income 320.5 451.9 Net change in amortization, impairment and provisions 92.5 (a) 90.1 (b) Gains and losses on Corporate actions 10.0 0.4 Cash flow from operating activities 423.0 542.3 Change in inventories -8.6 (c) 27.5 Change in trade receivables -33.0 (d) -28.1 Change in trade payables and other operating working capital -1.9 116.8 Change in operating working capital requirement -43.5 116.1 Change in receivables, net of tax -16.5 (e) -1.7 Total change in working capital requirement -60.0 114.5 Net cash from operating activities 362.9 656.8 Capital expenditure -230.7 (f) -84.5 Income from sales of fixed assets 2.0 2.5 Change in net trade payables on fixed assets 4.9 -1.0 Acquisition of equity investments, subscr. to capital increases net of reductions -192.7 (g) -168.9 (h) Net change in advances and loans to subsidiaries 3.2 (i) 12.2 Net change in other non-current financial assets -3.4 0.4 Net cash flows from (used in) investment activities -416.7 -239.3 Dividends paid -106.1 -100.2 Capital expenditure subsidy 0.1 Merger 0.4 Net cash used in shareholders' equity -106.1 -99.8 Change in net debt (excluding exchange rate impact) -159.9 317.7 Breakdown of change in net debt Net debt at beginning of year 50.3 368.3 Impact of changes in exchange rates on net debt 0.7 -0.3 Impact of impairments of cash and cash equivalents 0.1 0.1 Change in net debt 159.9 -317.7 6.0 -0.3 153.9 -317.4 NET DEBT AT END OF YEAR 210.9 50.3 Committed debt Cash and bank overdrafts Including amortization and impairment of property, plant, and equipment and intangible assets for €52.7 million, provisions for risks on securities of €55.9 million, deferred expenses of €0.1 million, net reversals of inventory impairment losses of €0.3 million, net reversals of provisions for risks and charges of €1.7 million, and impairment losses on receivables of €14.3 million. Including amortization and impairment of property, plant and equipment and intangible assets (€58 million), additions for risk on securities (€27.5 million), net additions to regulated provisions (€5.1 million), net additions to provisions for contingencies and losses (€5.1 million), net reversals of impairment of inventories (-€2.6 million) and impairment of receivables (-€2.9 million). Including an increase in inventories of €13.9 million. Including increases in Group trade receivables of €25.8 million, export trade receivables of €4.8 million, and domestic trade receivables of €2.3 million. Including a provision for the 2025 research tax credit of €15.9 million and tax disbursements of €4 million. Including property, plant and equipment for -€101.1 million (see Note 4.3) and intangible assets for -€129.7 million (see Note 4.2). Including acquisition of an equity investment in SpinChip Diagnostic ASA of -€112.3 million, capital increases in subsidiaries of -€77.9 million (detailed in Note 4.4) and subscription to the capital increase of Aurobac Therapeutics SAS of -€2.5 million. Including capital increases for subsidiaries of -€123.7 million, acquisition of an equity investment in bioMérieux Mexico of -€24.7 million, SpinChip Diagnostics ASA of -€10.9 million, Lumed Inc. of -€9.1 million, and release of capital in bioMérieux Nigeria of -€0.4 million. Including repayment of the intra-group loan to bioMérieux Egypt of €3.2 million. Debt refinancing At December 31, 2025, bioMérieux SA had a syndicated credit facility of €600 million. This syndicated credit facility matures in March 2028 (5 years). Following the exercise of two extension options in February 2024 and January 2025, its maturity was extended to 2030. On February 12, 2024, bioMérieux amended this syndicated credit facility agreement to include a margin adjustment mechanism based on the achievement of four Environmental, Social and Governance metrics. This syndicated credit facility has not been drawn on at December 31, 2025. A €200 million Euro PP bond issue was launched in June 2020. It consists of two tranches, including a 10-year €55 million tranche at a rate of 1.902% and a seven-year €145 million tranche at a rate of 1.5%. This syndicated credit facility and the Euro PP bond are subject to the following covenant: bioMérieux Group net debt may not exceed 3.5 times operating income before non-recurring items (EBITDA) before depreciation/amortization and acquisition-related costs. The Company complied with this covenant at December 31, 2025. bioMérieux SA also has negotiable debt securities amounting to €16 million at December 31, 2025, compared with €10 million at December 31, 2024. Change Breakdown of financial debts In millions of euros 12/31/2025 12/31/2024 Bond issues 201.6 201.6 Bank overdrafts and financial instruments 1.6 0.6 Borrower cash pooling 609.6 711.8 Other borrowings 20.5 (a) 14.6 TOTAL BORROWINGS 833.4 928.6 (a) Of which negotiable debt securities amounting to €16 million at December 31, 2025, compared with €10 million at December 31, 2024. Debt schedule Net debt by maturity In millions of euros 12/31/2025 12/31/2024 Due beyond 5 years - 55.0 Due in 1 to 5 years 204.5 (a) 149.6 Total due beyond 1 year 204.5 204.6 In less than one year 628.8 (b) 724.1 Total borrowings 833.4 928.6 Cash investments -213.6 (c) -172.9 Cash assets, financial instruments and lender cash pooling -408.8 (d) -705.5 NET DEBT 210.9 50.3 Including a bond issue of €200 million (compared with €145 million at December 31, 2024). Including borrower cash pooling of €609.6 million, versus €711.8 million at December 31, 2024, which included a debt owed to BioFire Diagnostics of €436.8 million, (versus €656.8 million at December 31, 2024). Cash investments are described in Note 8.2. ‌Including lender cash pooling for €224 million (compared with €529.8 million at December 31, 2024), including a receivable from Institut Mérieux of €62.9 million (nil at December 31, 2024) and from bioMérieux Inc. of €49.6 million (compared with €443.3 million at December 31, 2024). NOTE 13 Trade and other operating payables Trade and other payables In millions of euros 12/31/2025 12/31/2024 Trade payables 327.4 334.7 Tax and social-security debts 247.6 237.6 Debt to suppliers of non-current assets 31.1 27.2 Other payables 14.0 16.3 Deferred income 4.5 (a) 4.6 TOTAL 624.6 620.5 (a) Including rental and maintenance agreements for €3.9 million and the sale of reagents and instruments for €0.6 million. ‌NOTE 14 Debt schedule Statement of debt maturities at the end of the fiscal year In millions of euros Gross amounts Maturity within 1 year Maturity within 1 and 5 years Maturity over 5 years Borrowings and similar debt 833.4 628.8 204.5 - Trade payables 327.4 327.4 - - Other payables 292.7 198.1 23.5 71.1 Deferred income 4.5 4.2 0.3 - ‌TOTAL 1,458.0 1,158.6 228.3 71.1 NOTE 15 Accrued expenses and income Accrued expenses and income In millions euros 12/31/2025 12/31/2024 Miscellaneous borrowings and financial debt 1.7 1.7 Trade payables 55.3 54.3 Tax and social-security debts 228.8 219.9 Other operating payables 11.3 14.2 Other non-operating payables 14.2 11.5 TOTAL ACCRUED EXPENSES 311.2 301.6 TOTAL ACCRUED INCOME ‌32.5 (a) 53.7 (a) Including unbilled revenue of €31.2 million at December 31, 2025, compared with €46.7 million at December 31, 2024. NOTE 16 Sales Accounting principles Revenue from product sales (reagents and instruments) and related services (after-sales, training, delivery, etc.) are presented in "Sales" on the profit & loss statement. Sales arising from the sale of products is recognized when all of the following criteria have been satisfied: the significant risks and rewards of ownership have been transferred to the buyer; the Company no longer has a continuing involvement in the effective control over the goods sold; the revenue and the costs incurred or to be incurred in relation to the transaction can be measured reliably; it is probable that the economic benefits associated with the transaction will flow to the Company. These criteria are satisfied when reagents are delivered and when sold instruments are installed. In the case of services (training, after-sales service, etc.), sales are recognized only after the services have been rendered. Revenue from instrument maintenance contracts is deferred and recognized on the basis of the elapsed portion of the service contract. Sales are measured at the fair value of the consideration received or receivable, net of any discounts and rebates granted to customers. Sales taxes and value-added taxes are not included in sales. Change Breakdown of sales In millions of euros France Export Total 12/31/2025 Total 12/31/2024 Sale of goods 109.2 614.5 Sales of equipment and spare parts 8.1 159.6 723.7 167.7 672.8 154.0 Sales of reagents 101.1 454.0 555.1 518.3 Sales of services - 0.9 0.9 0.5 Production sold 122.7 847.9 Sales of equipment and spare parts 1.3 9.0 970.5 10.3 967.9 9.4 Sales of reagents 90.8 459.9 550.7 583.4 Sales of services 30.6 379.0 409.5 375.1 TOTAL 231.9 1,462.3 1,694.2 1,640.7 Sales by geographic area In millions of euros 12/31/2025 12/31/2024 France & Overseas France 235.5 240.0 Europe, Africa, Middle East 798.8 761.6 South America 55.5 54.0 North America 128.9 125.0 Asia Pacific 114.9 132.8 Other related activities not broken down 360.6 327.3 ‌TOTAL 1,694.2 1,640.7 NOTE 17 Research & Development expenses Research & Development expenses are recognized as expenses in the fiscal year in which they are incurred. ‌Research & Development expenses in fiscal year 2025 amounted to €195.8 million, compared to €166.3 million the previous year. NOTE 18 Personnel costs Change Personnel costs In millions of euros 12/31/2025 12/31/2024 Wages and salaries 246.3 242.4 Incentives, annual bonuses, and employee share ownership plans 76.0 63.9 Other personnel costs 8.1 8.0 Social security contributions 130.9 125.7 TOTAL 461.4 440.1 Pursuant to the statutory formula, the taxable net income for the 2025 fiscal year did not yield any amount in employee profit sharing. Compensation allocated to members of administrative, management and supervisory bodies and senior management bodies (Company directors and members of the Executive Committee who are employees of the Company) in respect of their duties for the fiscal year consisted of fixed and variable compensation of €9.5 million and directors' fees of €0.4 million. Headcount Breakdown of average headcount In full-time equivalent 2025 Production workers 491 Office workers, technicians, supervisors 1,070 Manager and engineers 2,555 ‌TOTAL 4,115 NOTE 19 Net financial income Accounting principles Dividends received are recognized net of withholding taxes applicable in the country of origin. Change Financial income In millions of euros Income Expenses 12/31/2025 Net 12/31/2024 Net Impairment of investments 0.1 -59.8 -59.7 (a) -28.1 Provisions for financial contingencies and losses 2.8 - 2.8 0.6 Impairment on cash pooling and loans 1.1 -0.1 1.0 0.0 Revenue from securities 349.9 - 349.9 (b) 480.3 Realized and unrealized foreign exchange gains and losses 119.8 -114.0 5.8 -0.4 Other financial income and expenses 26.8 -27.1 -0.2 (c) -0.3 TOTAL 500.4 -200.9 299.6 452.0 Including a net addition of €16.5 million for other fixed assets in 2025 (versus €27.3 million in 2024), and €10.2 million for equity investments in 2025 (versus €0.8 million in 2024). Including bioMérieux Inc. dividend payment of €303.8 million in 2025 (vs. €429.5 million in 2024). Dividends received from subsidiaries are described in the list of subsidiaries and minority interests in Note 4.4.3. Including a net financial expense of €8.1 million in interest on cash pooling (vs. €6.8 million in 2024). Foreign exchange gains and losses Foreign exchange gains and losses result from differences between the transaction exchange rate and the settlement rate (or the year-end rate if the payment has not yet been made). These differences only partially reflect the impact of currency fluctuations. Foreign exchange gains and losses on commercial transactions are recognized under the relevant headings in the profit & loss statement. Foreign exchange gains and losses affect the profit & loss statement as follows: In millions of euros 12/31/2025 12/31/2024 Operation 2.4 -6.8 Financial items 5.8 -0.4 TOTAL 8.2 -7.2 ‌NOTE 20 Non-recurring income Non-recurring income In millions of euros Income Expenses Net 12/31/2025 Net 12/31/2024 Exits and disposals of fixed assets - - - -0.1 Statutory provisions 14.0 -14.0 -0.0 -5.1 Other non-recurring income and expenses - - - 2.1 TOTAL 14.0 -14.0 -0.0 -3.1 ‌Following the application of the new ANC 2022-06 Regulation, income and expenses recorded as non-recurring income are limited to accounting entries of a purely tax nature. The new provisions of the Regulation apply from 2025, with no changes to the 2024 financial statements. In 2025, no income or expense directly related to a major or extraordinary event, a change in method or an error correction was recorded as non-recurring income. NOTE 21 Corporate income tax Breakdown and changes in corporate income tax Corporate income tax in 2025 showed net income of €11.9 million, versus a net income of €16.7 million the previous year. In millions of euros Before tax Tax 12/31/2025 After tax 12/31/2024 After tax Recurring income 308.7 11.9 320.5 453.1 Non-recurring income -0.0 0.0 -0.0 -1.2 NET INCOME FOR THE YEAR 308.6 11.9 320.5 451.9 Tax credits and reductions The Company recognized several tax credits for 2025 totaling €20.7 million. Tax credits and reductions In millions of euros 2025 Research tax credit 15.9 Tax reduction for sponsorship 3.8 Foreign tax credits 0.9 Family tax credit 0.1 TOTAL 20.7 Net income for the year excluding provisions recognized for tax purposes There were no expenses for accelerated depreciation, amortization and regulated provisions in 2025, compared with €5.1 million in 2024. As a result, these special tax assessments will not generate any tax savings in 2025. 2025 Universal Registration Document

View stock analysis, news, and events for Biomerieux Sa